2-甲基-1-[(4-甲基苯基)磺酰基]-1H-吡咯并[2,3-b]吡啶 | 1019436-10-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-1-[(4-甲基苯基)磺酰基]-1H-吡咯并[2,3-b]吡啶
• 英文名称: 2-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 1H-Pyrrolo[2,3-B]pyridine, 2-methyl-1-[(4-methylphenyl)sulfonyl]-；2-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine
• CAS: 1019436-10-2
• 化学式: C₁₅H₁₄N₂O₂S
• 分子量: 286.354
• InChiKey: ITTUUMMJUZJOLL-UHFFFAOYSA-N

物化性质

• 沸点：
  482.9±47.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基-1-[(4-甲基苯基)磺酰基]-1H-吡咯并[2,3-b]吡啶 在 三乙基硅烷 、 aluminum (III) chloride 、 potassium hydroxide 、 lithium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 三氟乙酸 为溶剂， 反应 36.0h， 生成 2-甲基-1H-吡咯并[2,3-b]吡啶-3-乙酸
  参考文献：
  名称：

  Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity

  摘要：

  Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity based probe, could be used to pull down active endogenous KLK6.

  DOI：

  10.1021/acs.jmedchem.8b01106
• 作为产物：
  描述：

  7-氮杂吲哚 在 正丁基锂 、 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 5.0h， 生成 2-甲基-1-[(4-甲基苯基)磺酰基]-1H-吡咯并[2,3-b]吡啶
  参考文献：
  名称：

  Palladium-Catalyzed Three-Component Dearomatization/Sulfonylation Cascade

  摘要：

  DOI：

  10.1021/acs.orglett.2c01382

文献信息

• Asymmetric Hydrogenation of Azaindoles: Chemo‐ and Enantioselective Reduction of Fused Aromatic Ring Systems Consisting of Two Heteroarenes
  作者：Yusuke Makida、Masahiro Saita、Takahiro Kuramoto、Kentaro Ishizuka、Ryoichi Kuwano

  DOI：10.1002/anie.201606083

  日期：2016.9.19

  by using the chiral catalyst, which was prepared from [Ru(η3‐methallyl)2(cod)] and a trans‐chelating bis(phosphine) ligand (PhTRAP). The dearomative reaction exclusively occurred on the five‐membered ring, thus giving the corresponding azaindolines with up to 97:3 enantiomer ratio.

  高对映选择性通过使用手性催化剂，将其从的[Ru（η制备的氮杂吲哚的氢化实现3 -methallyl）2（COD）]和反式-chelating双（膦）配体（PhTRAP）。脱芳香反应只发生在五元环上，因此相应的氮杂吲哚啉对映体比率高达97：3。
• Regioselective C–H sulfenylation of <i>N</i>-sulfonyl protected 7-azaindoles promoted by TBAI: a rapid synthesis of 3-thio-7-azaindoles
  作者：Jingyan Hu、Xiaoming Ji、Shuai Hao、Mingqin Zhao、Miao Lai、Tianbao Ren、Gaolei Xi、Erbin Wang、Juanjuan Wang、Zhiyong Wu

  DOI：10.1039/d0ra06635d

  日期：——

  This paper describes the regioselective C-3 sulfenylation of N-sulfonyl protected 7-azaindoles with sulfonyl chlorides. In this transformation, dual roles of TBAI serving as both promoter and desulfonylation reagent have been demonstrated. The reaction proceeded smoothly under simple conditions to afford 3-thio-7-azaindoles in moderate to good yields with broad substrate scopes. This protocol refrains

  本文描述了用磺酰氯对N-磺酰基保护的 7-氮杂吲哚进行区域选择性 C-3 亚磺酰化。在这种转化中，TBAI 作为促进剂和脱磺酰化试剂的双重作用已经得到证实。该反应在简单的条件下顺利进行，以中等至良好的收率得到具有广泛底物范围的3-硫代-7-氮杂吲哚。该协议避免使用过渡金属催化剂、强氧化剂或碱，并显示其在有机合成中的实用合成价值。
• NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7
  申请人：Leroy Vincent

  公开号：US20090253679A1

  公开（公告）日：2009-10-08

  The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.

  本发明涉及式(I)的咪唑酮衍生物，涉及制备这种衍生物的方法、中间体、包含这种衍生物的药物组合物、抑制蛋白激酶的方法以及包括给予这种衍生物的治疗方法。
• NOUVEAUX DERIVES IMIDAZOLONES, LEUR PREPARATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES, UTILISATION COMME INHIBITEURS DE PROTEINES KINASES NOTAMMENT CDC7
  申请人：Sanofi-Aventis

  公开号：EP2094699B1

  公开（公告）日：2011-07-20
• US8314121B2
  申请人：——

  公开号：US8314121B2

  公开（公告）日：2012-11-20